Greenland Mines Ltd GRML

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Mines"), formerly known as Klotho Neurosciences, Inc., develops essential medicines for the treatment of chronic diseases –

cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio

and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which

uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative

Last close 5.78 2026-10-23
Market cap $918.2M 2026-06-30 share count
52-week range 2.82 - 27.48

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.22

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021
R&D $634.2K$0$0——
SG&A $3.1M$2.8M$30.5K$534.0K—
Total operating expenses $7.1M$5.5M$631.3K$153.1K—
Operating income -$7.1M-$5.5M-$631.3K-$657.0K—
Interest expense $2.3M$356.6K$76.2K——
Pre-tax income -$10.6M-$6.2M-$707.5K$1.6M—
Income tax ——$690.6K$322.0K—
Net income -$10.6M-$6.2M-$707.5K$1.2M—
EPS, basic -0.22-0.32-0.05——
EPS, diluted -0.22-0.32-0.05——
Shares, diluted (wtd. avg.) 48.5M19.2M15.1M——

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021
Cash and equivalents $7.2M$63.7K$2.8K$75.9K$5.0K
Total current assets $7.3M$157.8K$6.6K$440.2K$5.0K
Total assets $9.6M$2.5M$2.2M$118.2M$5.0K
Accounts payable $44.6K$63.7K$151.3K——
Short-term debt ———$300.0K—
Total current liabilities $76.8K$1.2M$1.6M$506.2K$8.5K
Total liabilities $129.8K$1.3M$1.6M$4.9M$8.5K
Retained earnings -$21.1M-$10.6M-$3.9M-$4.0M-$3.6K
Total equity $9.5M$1.2M-$442.7K-$4.0M-$3.6K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021
Operating cash flow -$5.9M-$2.9M-$446.9K-$493.0K—
Stock-based compensation $1.6M$2.6M———
Investing cash flow —-$123.5K$23.9K-$116.2M—
Financing cash flow $13.0M$3.1M$350.0K$117.0M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-090213.

Plot the figures US dollars

  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -15M -10M -5M 0 5M Net income, FY2022: 1.2M Net income, FY2023: -707.5K Net income, FY2024: -6.2M Net income, FY2025: -10.6M FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2021FY2022FY2023FY2024FY2025
Revenue — — — — —
Gross profit — — — — —
Net income — $1.2M -$707.5K -$6.2M -$10.6M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed Item 1.01
  • Shareholder vote Item 5.07
  • Material agreement signed Item 1.01
  • Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%